Search research articles
Contact Us
Filters
Showing results (531-540 of 548) with videos related to
Page
of 55
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Jaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Biomaterials
|
May 4, 2019
Multiscale analyses reveal native-like lamellar bone repair and near perfect bone-contact with porous strontium-loaded bioactive glass
H Autefage, F Allen, H M Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
Asma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
William F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Jennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer
Mirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C West, Masha Kocherginsky, Eva Y Tonsing-Carter, et al.
Blood
|
November 15, 2013
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Blood
|
February 21, 2020
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice
Ekta Seth Chhabra, Tongyao Liu, John Kulman, et al.
Page
of 55
Search research articles
Search
Showing results (531-540 of 548) with videos related to
Sort By:
Page
of 55
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Jaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Biomaterials
|
May 4, 2019
Multiscale analyses reveal native-like lamellar bone repair and near perfect bone-contact with porous strontium-loaded bioactive glass
H Autefage, F Allen, H M Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
Asma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
William F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Jennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer
Mirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C West, Masha Kocherginsky, Eva Y Tonsing-Carter, et al.
Blood
|
November 15, 2013
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Blood
|
February 21, 2020
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice
Ekta Seth Chhabra, Tongyao Liu, John Kulman, et al.
Page
of 55